Ilana Schlam

1.1k total citations · 1 hit paper
41 papers, 535 citations indexed

About

Ilana Schlam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ilana Schlam has authored 41 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Ilana Schlam's work include HER2/EGFR in Cancer Research (19 papers), Advanced Breast Cancer Therapies (12 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Ilana Schlam is often cited by papers focused on HER2/EGFR in Cancer Research (19 papers), Advanced Breast Cancer Therapies (12 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Ilana Schlam collaborates with scholars based in United States, Italy and Canada. Ilana Schlam's co-authors include Sandra M. Swain, Sara M. Tolaney, Paolo Tarantino, Rafaël Fonseca, Sinto Sebastian, Jill Adamski, Filipa Lynce, Margaret E. Gatti‐Mays, Harini A. Chakkera and Stefania Morganti and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ilana Schlam

38 papers receiving 527 citations

Hit Papers

HER2-positive breast cancer and tyrosine kinase inhibitor... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
    2021 176 citations Ilana Schlam, Sandra M. Swain npj Breast Cancer profile →

Peers

Ilana Schlam
Xiaohong Yan United States
Chenyi Liang China
Jeanne Fourie Zirkelbach United States
Lavina Bharwani Singapore
Kenichi Harano Japan
Koichi Sakaguchi Japan
Alex Vo United States
J.-M. Nabholtz Canada
Rama Krishna Kancha India
Jolien Van den Bossche Belgium
Xiaohong Yan United States
Ilana Schlam
Citations per year, relative to Ilana Schlam Ilana Schlam (= 1×) peers Xiaohong Yan

Countries citing papers authored by Ilana Schlam

Since Specialization
Citations

This map shows the geographic impact of Ilana Schlam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilana Schlam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilana Schlam more than expected).

Fields of papers citing papers by Ilana Schlam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilana Schlam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilana Schlam. The network helps show where Ilana Schlam may publish in the future.

Co-authorship network of co-authors of Ilana Schlam

This figure shows the co-authorship network connecting the top 25 collaborators of Ilana Schlam. A scholar is included among the top collaborators of Ilana Schlam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilana Schlam. Ilana Schlam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Diana, Shayesteh Jahanfar, Joshua Dower, et al.. (2025). Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Breast Cancer Research. 27(1). 38–38. 1 indexed citations
2.
Patel, Pooja, et al.. (2025). Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions. npj Breast Cancer. 11(1). 81–81. 1 indexed citations
3.
Leone, José Pablo, Julieta Leone, Faina Nakhlis, et al.. (2024). Survival outcomes and treatment patterns by tumor subtype (TS) in stage III inflammatory and non-inflammatory breast cancer (BC).. Journal of Clinical Oncology. 42(16_suppl). 607–607. 1 indexed citations
4.
Hirko, Kelly A., Faina Nakhlis, Jennifer R. Bellon, et al.. (2024). Abstract PO1-09-10: County-level Social Vulnerability and Survival among Women with Inflammatory Breast Cancer. Cancer Research. 84(9_Supplement). PO1–9. 1 indexed citations
5.
Song, Fei, et al.. (2024). Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?. Current Oncology Reports. 26(1). 21–33. 6 indexed citations
6.
Schlam, Ilana, Chiara Corti, Sarah Sammons, Elizabeth A. Mittendorf, & Sara M. Tolaney. (2024). Checkpoint inhibition for early-stage hormone receptor-positive breast cancer. Expert Opinion on Biological Therapy. 24(6). 511–520. 3 indexed citations
7.
James, Ted A., et al.. (2024). Breast cancer treatment delay and the Hispanic paradox: A SEER database analysis. The American Journal of Surgery. 244. 116135–116135. 3 indexed citations
8.
9.
Schlam, Ilana & Mariana Chávez‐MacGregor. (2024). Best of the year: Advanced breast cancer in 2023. The Breast. 74. 103677–103677. 6 indexed citations
10.
11.
Schlam, Ilana, et al.. (2023). Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2. Critical Reviews in Oncology/Hematology. 190. 104090–104090. 16 indexed citations
12.
Corti, Chiara, Edward Christopher Dee, Ilana Schlam, et al.. (2023). Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow. European Journal of Cancer. 198. 113504–113504. 3 indexed citations
13.
Schlam, Ilana, Paolo Tarantino, & Sara M. Tolaney. (2023). Managing adverse events of sacituzumab govitecan. Expert Opinion on Biological Therapy. 23(11). 1103–1111. 12 indexed citations
14.
Schlam, Ilana, Sara M. Tolaney, & Paolo Tarantino. (2023). The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. Expert Review of Anticancer Therapy. 24(11). 1059–1066. 1 indexed citations
15.
Schlam, Ilana, et al.. (2023). Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan. Current Oncology Reports. 25(12). 1467–1482. 1 indexed citations
16.
Schlam, Ilana, Raquel Nunes, & Filipa Lynce. (2022). Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer. OncoTargets and Therapy. Volume 15. 471–478. 10 indexed citations
17.
Schlam, Ilana, Paolo Tarantino, Stefania Morganti, et al.. (2022). Emerging Targeted Therapies for Early Breast Cancer. Drugs. 82(14). 1437–1451. 8 indexed citations
18.
Schlam, Ilana, S. Church, Tyler Hether, et al.. (2021). The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling. Journal of Translational Medicine. 19(1). 480–480. 24 indexed citations
19.
Schlam, Ilana, et al.. (2017). Myositis-like Chronic Graft Versus Host Disease: Case Series and Literature Review. Blood. 130. 5508–5508. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaohong Yan Breakdown of academic impact, for papers by Chenyi Liang Breakdown of academic impact, for papers by Jeanne Fourie Zirkelbach Breakdown of academic impact, for papers by Lavina Bharwani Breakdown of academic impact, for papers by Kenichi Harano Breakdown of academic impact, for papers by Koichi Sakaguchi Breakdown of academic impact, for papers by Alex Vo Breakdown of academic impact, for papers by J.-M. Nabholtz Breakdown of academic impact, for papers by Rama Krishna Kancha Breakdown of academic impact, for papers by Jolien Van den Bossche
Rankless by CCL
2026